HONG KONG, Mar 25, 2022 – (ACN Newswire) – Redsun Services Group Limited (“Redsun Services”…
HONG KONG, Mar 25, 2022 – (ACN Newswire) – Angelalign Technology Inc. (“Angelalign” or “Company”;…
NEW YORK–(BUSINESS WIRE)–Blackstone Mortgage Trust, Inc. (NYSE: BXMT) (the “Company”) today announced the pricing of…
Singapore, Mar 25, 2022 – (ACN Newswire) – Their gender itself is reason enough for…
Singapore, Mar 25, 2022 – (ACN Newswire) – Memiontec Holdings Ltd. (“Memiontec” or the “Company”,…
UserTesting helps companies innovate new ways to engage with customers as digital transformation continues to…
Personalis’ oncology diagnostics business expected to build on foundation of advanced technology already the driver…
Customers will continue to be served through their respective Citizens and Investors branches, websites and…
FORT COLLINS, Colo., March 24, 2022 (GLOBE NEWSWIRE) — Statera Biopharma, Inc. (NASDAQ: STAB) (the…
Continued Progress Towards Optimizing Clinical Development Plans On Track to Initiate Phase 2b Study of…
Pipeline Advancement Continues with Ongoing Phase 2 Studies for Voriconazole and Tacrolimus Programs Partnership Activity…
— Proposal of one-tier board structure & appointment of three new directors — Mechelen, Belgium;…
TORONTO, March 24, 2022 (GLOBE NEWSWIRE) — Auxly Cannabis Group Inc. (TSX – XLY) (OTCQX:…
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) — Imago BioSciences, Inc. (“Imago”) (Nasdaq:…
WINNIPEG, Manitoba, March 24, 2022 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the…
– Confirmed partial response in one of the first three metastatic castration-resistant prostate cancer (mCRPC)…
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (NASDAQ:…
BILLERICA, Mass., March 24, 2022 (GLOBE NEWSWIRE) — SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ:…
MINNEAPOLIS, March 24, 2022 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing…
On track to report topline data from ACT-AD Phase 2 Alzheimer’s disease study in 2Q22…